Drugs / Epirubicin
last change 10 days ago re-read 8 days ago

Epirubicin

Small molecule

Developed for
breast cancer · gastric cancer · triple-negative breast carcinoma · female breast carcinoma · esophageal cancer · hepatocellular carcinoma · lymphoma · diffuse large B-cell lymphoma
+79 more · HER2 positive breast carcinoma · breast neoplasm · Her2-receptor negative breast cancer · hormone receptor-positive breast cancer · cancer of unknown primary site · soft tissue sarcoma · esophageal adenocarcinoma · gastroesophageal junction adenocarcinoma · ovarian cancer · small cell lung carcinoma · adenoid cystic carcinoma · bile duct cancer · gastric adenocarcinoma · gastroesophageal cancer · leiomyosarcoma · liver cancer · nasopharyngeal carcinoma · non-invasive bladder urothelial carcinoma · non-small cell lung carcinoma · pancreatic adenocarcinoma · plasma cell myeloma · prostate cancer · small intestine cancer · superficial urinary bladder carcinoma · adenocarcinoma · breast adenocarcinoma · carcinoma of esophagus · childhood germ cell tumor · classic Hodgkin lymphoma · cutaneous melanoma · ductal breast carcinoma in situ and lobular carcinoma in situ · endometrial cancer · extragonadal germ cell tumor · fallopian tube cancer · gallbladder cancer · gastric neoplasm · gastroesophageal adenocarcinoma · germ cell tumor · head and neck cancer · high grade B-cell lymphoma · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement · infectious disease with sepsis · inflammatory breast carcinoma · invasive breast carcinoma · invasive lobular breast carcinoma · leukemia · liposarcoma · luminal B breast carcinoma · lung cancer · malignant epithelial tumor of ovary · malignant mesothelioma · malignant testicular germ cell tumor · mantle cell lymphoma · marginal zone lymphoma · nasal cavity and paranasal sinus carcinoma · neoplasm · neoplasm of testis · non-Hodgkin lymphoma · pancreatic ductal adenocarcinoma · peritoneum cancer · plasma cell leukemia · pleomorphic rhabdomyosarcoma · retroperitoneal sarcoma · rhabdomyosarcoma · sarcoma · testicular germ cell tumor · undifferentiated high grade pleomorphic sarcoma of bone · urinary bladder cancer · urothelial carcinoma · yolk sac tumor · acute lymphoblastic leukemia · B-cell non-Hodgkin lymphoma · breast mucinous carcinoma · endometrial carcinoma · invasive tubular breast carcinoma · peripheral T-cell lymphoma, not otherwise specified · thymoma · urinary bladder carcinoma · urinary bladder neoplasm
Investigated by
National Cancer Institute (NCI) · Fudan University · Pfizer · Amgen · European Organisation for Research and Treatment of Cancer - EORTC · GBG Forschungs GmbH
+262 more · UNICANCER · Henan Cancer Hospital · Celgene Corporation · Guangdong Provincial People's Hospital · Hoffmann-La Roche · Chinese Academy of Medical Sciences · Hellenic Oncology Research Group · Jiangsu HengRui Medicine Co., Ltd. · NCIC Clinical Trials Group · NSABP Foundation Inc · Ruijin Hospital · Second Affiliated Hospital, School of Medicine, Zhejiang University · University Hospital of Crete · Alliance for Clinical Trials in Oncology · Aventis Pharmaceuticals · Bristol-Myers Squibb · Cancer Trials Ireland · Dana-Farber Cancer Institute · Eli Lilly and Company · First Affiliated Hospital of Zhejiang University · IRCCS San Raffaele · M.D. Anderson Cancer Center · Medical Research Council · Memorial Sloan Kettering Cancer Center · Merck Sharp & Dohme LLC · National Health Research Institutes, Taiwan · Pharmacia · Royal Marsden NHS Foundation Trust · SCRI Development Innovations, LLC · Sanofi · Shanghai Jiao Tong University School of Medicine · Swedish Breast Cancer Group · Tianjin Medical University Cancer Institute and Hospital · AHS Cancer Control Alberta · Austrian Breast & Colorectal Cancer Study Group · Auxilio Mutuo Cancer Center · Breast International Group · Brigham and Women's Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Case Comprehensive Cancer Center · Centre Jean Perrin · Centro di Riferimento Oncologico - Aviano · China Medical University Hospital · Chinese Anti-Cancer Association · Daiichi Sankyo · ETOP IBCSG Partners Foundation · Eye & ENT Hospital of Fudan University · First Hospital of China Medical University · GERCOR - Multidisciplinary Oncology Cooperative Group · Genentech, Inc. · Georgetown University · GlaxoSmithKline · Gustave Roussy, Cancer Campus, Grand Paris · Hospital Centre Biel/Bienne · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · Institute of Cancer Research, United Kingdom · International Society of Pediatric Oncology · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Kaohsiung Veterans General Hospital. · Karolinska University Hospital · Massachusetts General Hospital · National Taiwan University Hospital · Nordic Society of Gynaecological Oncology - Clinical Trials Unit · Peking University People's Hospital · Pharmacia and Upjohn · Rigshospitalet, Denmark · Shandong Cancer Hospital and Institute · Sichuan Provincial People's Hospital · Spanish Breast Cancer Research Group · Study Group of Medical Tumour Therapy (AGMT) · Swiss Cancer Institute · The First Affiliated Hospital with Nanjing Medical University · Trans Tasman Radiation Oncology Group · Universitaire Ziekenhuizen KU Leuven · all 268 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) ELLENCE — 2005-03-02 fda.gov ↗
Approved US (FDA) ELLENCE — 1999-09-15 fda.gov ↗

Trials 257 · started per year

today
US approved 1999
1
1
2
3
5
4
7
3
9
13
13
14
10
10
9
13
11
9
7
4
3
9
6
6
9
10
4
5
8
9
11
7
7
7
5
199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT00215514 Sep 2000 → Nov 2003 gastric cancer, gastroesophageal cancer Dana-Farber Cancer Institute Completed No outcome recorded
Phase 114 trials
Phase 1 NCT06766266 Jan → Apr 2025 overdue non-invasive bladder urothelial carcinoma First Affiliated Hospital of Chongqing Medical University Recruiting No outcome recorded
Phase 1 NCT06699576 Dec 2024 → Dec 2026 expected osteosarcoma, soft tissue sarcoma Hansoh BioMedical R&D Company Not yet recruiting No outcome recorded
Phase 1 NCT02897700 Jan 2013 → Dec 2026 expected breast cancer Shanghai Jiao Tong University School of Medicine Recruiting No outcome recorded
Phase 1 NCT00878904 Sep 2009 → May 2013 cancer of unknown primary site University of California, San Francisco Completed No outcome recorded
Phase 1 NCT00722293 Jul 2008 → Jun 2012 breast neoplasm GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00753207 Oct 2007 → Nov 2008 breast cancer Cancer Trials Ireland Completed No outcome recorded
Phase 1 NCT00322374 Aug 2006 → Feb 2009 breast cancer R-Pharm Completed No outcome recorded
Phase 1 NCT02392845 Jun 2005 → Mar 2009 breast cancer Hospices Civils de Lyon Completed No outcome recorded
Phase 1 NCT00486356 Oct 2004 → Jan 2010 bile duct cancer, gallbladder cancer, gastric cancer University of Nebraska Completed No outcome recorded
Phase 1 NCT00096304 Jun 2004 → Sep 2006 prostate cancer Medical University of South Carolina Terminated No outcome recorded Stop: Enrollment
Phase 1/210 trials
Phase 1/2 NCT04836156 Apr 2021 → Jun 2022 overdue Her2-receptor negative breast cancer Peking University People's Hospital Recruiting No outcome recorded
Phase 1/2 NCT04213898 Jan 2020 → Jan 2021 triple-negative breast carcinoma Henan Cancer Hospital Unknown No outcome recorded
Phase 1/2 NCT03277924 May 2017 → Jun 2024 bone sarcoma, soft tissue sarcoma Spanish Group for Research in Sarcomas Completed No outcome recorded
Phase 1/2 NCT03356860 Apr 2017 → Nov 2022 luminal B breast carcinoma, triple-negative breast carcinoma Grand Hôpital de Charleroi Completed No outcome recorded
Phase 1/2 NCT00705315 May 2008 → Jun 2010 breast cancer Hellenic Oncology Research Group Completed No outcome recorded
Phase 1/2 NCT00130936 Oct 2005 → Nov 2007 esophageal cancer, gastric cancer AHS Cancer Control Alberta Terminated No outcome recorded
Phase 1/2 NCT00066443 Nov 2003 → Jan 2010 breast cancer NCIC Clinical Trials Group Completed No outcome recorded
Phase 1/2 NCT00057980 Oct 2002 → Feb 2007 liver cancer Northwestern University Completed No outcome recorded
Phase 1/2 NCT00021047 Jul 2001 → Jun 2004 bile duct cancer, cancer of unknown primary site, esophageal cancer, gastric cancer +1 National Institutes of Health Clinical Center (CC) Completed No outcome recorded
Phase 1/2 NCT00097383 — breast cancer Eli Lilly and Company Completed No outcome recorded
Phase 2128 trials · 4 met primary · 2 missed
Phase 2 NCT06227065 Dec 2026 → Nov 2030 expected non-invasive bladder urothelial carcinoma Hospital Centre Biel/Bienne Not yet recruiting No outcome recorded
Phase 2 NCT07801898 Sep 2026 → Sep 2028 expected invasive breast carcinoma The Second Hospital of Anhui Medical University Not yet recruiting No outcome recorded
Phase 2 NCT07616141 Jun 2026 → Jun 2028 expected adenoid cystic carcinoma Eye & ENT Hospital of Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT07320508 Jan 2026 → Dec 2027 expected adenoid cystic carcinoma, nasal cavity and paranasal sinus carcinoma Eye & ENT Hospital of Fudan University Recruiting No outcome recorded
Phase 2 NCT07351487 Sep 2025 → Sep 2028 expected triple-negative breast carcinoma First Affiliated Hospital of Zhejiang University Recruiting No outcome recorded
Phase 2 NCT06874933 May 2025 → Apr 2027 expected hormone receptor-positive breast cancer First Affiliated Hospital of Zhejiang University Recruiting No outcome recorded
Phase 2 NCT06797635 Mar 2025 → Dec 2029 expected breast cancer Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 2 NCT06291064 Mar 2025 → Jun 2029 expected triple-negative breast carcinoma University of Chicago Recruiting No outcome recorded
Phase 2 NCT06964906 Mar 2025 → Dec 2027 expected Her2-receptor negative breast cancer Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 2 NCT06692491 Jan 2025 → Dec 2027 expected — Peking University Shenzhen Hospital Not yet recruiting No outcome recorded
Show all 128 trials opens the full record — a long page
Phase 2/310 trials · 2 met primary · 1 missed
Phase 2/3 NCT04576143 Sep 2020 → Jun 2023 overdue Her2-receptor negative breast cancer Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 2/3 NCT03373708 Dec 2017 → Dec 2019 breast cancer Zhiyong Yu Unknown No outcome recorded
Phase 2/3 NCT03349177 Nov 2017 → Nov 2019 breast cancer Zhiyong Yu Unknown No outcome recorded
Phase 2/3 NCT02641847 Jan 2016 → Dec 2023 overdue female breast carcinoma, triple-negative breast carcinoma Fudan University Active not recruiting Met primary
Phase 2/3 NCT01787539 Feb 2013 → Feb 2017 gastric cancer Medical University of Lublin Unknown No outcome recorded
Phase 2/3 NCT01779206 May 2012 → Sep 2019 breast cancer West German Study Group Completed Met primary
Phase 2/3 NCT01924819 Sep 2009 → Dec 2026 expected gastric cancer Australasian Gastro-Intestinal Trials Group Active not recruiting Missed primary
Phase 2/3 NCT00843934 Mar 2009 → Dec 2012 hepatocellular carcinoma Nihon University Unknown No outcome recorded
Phase 2/3 NCT00525642 Jun 2003 → Jun 2015 breast cancer Fudan University Unknown No outcome recorded
Phase 2/3 NCT00960284 Jun 2003 → Jun 2009 pancreatic adenocarcinoma IRCCS San Raffaele Completed No outcome recorded
Phase 371 trials · 8 met primary · 12 missed
Phase 3 NCT07016126 Dec 2024 → Dec 2027 expected non-small cell lung carcinoma Guangdong Provincial People's Hospital Recruiting No outcome recorded
Phase 3 NCT05871918 Oct 2022 → Dec 2023 HER2 positive breast carcinoma Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded
Phase 3 NCT05474690 May 2022 → Mar 2023 HER2 positive breast carcinoma Henan Cancer Hospital Withdrawn No outcome recorded
Phase 3 NCT05121350 Mar 2022 → Jun 2024 soft tissue sarcoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 3 NCT05097443 Apr 2021 → Dec 2023 high grade B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, mantle cell lymphoma Shandong Provincial Hospital Unknown No outcome recorded
Phase 3 NCT04031677 Jan 2021 → Apr 2027 expected leiomyosarcoma, liposarcoma, retroperitoneal sarcoma European Organisation for Research and Treatment of Cancer - EORTC Recruiting No outcome recorded
Phase 3 NCT03151044 Jul 2016 → Jul 2017 diffuse large B-cell lymphoma FENG Ji-feng Unknown No outcome recorded
Phase 3 NCT02532400 Mar 2016 → Mar 2019 breast cancer Ruijin Hospital Terminated No outcome recorded Stop: Enrollment
Phase 3 NCT02363400 Dec 2014 → Dec 2021 nasopharyngeal carcinoma National Health Research Institutes, Taiwan Terminated No outcome recorded Stop: Enrollment
Phase 3 NCT02109146 Mar 2014 → May 2023 hepatocellular carcinoma Zhejiang University Completed No outcome recorded
Phase 412 trials · 1 met primary · 1 missed
Phase 4 NCT05420454 Jul 2022 → Jun 2027 expected breast cancer Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 4 NCT05420467 Jul 2022 → Jul 2027 expected breast cancer Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 4 NCT04137640 Jul 2021 → Nov 2025 breast cancer Shengjing Hospital Unknown No outcome recorded
Phase 4 NCT03799679 Nov 2018 → Nov 2019 triple-negative breast carcinoma Fudan University Unknown No outcome recorded
Phase 4 NCT03355157 Mar 2018 → Aug 2024 breast cancer GBG Forschungs GmbH Completed No outcome recorded
Phase 4 NCT03513601 Jul 2017 → May 2019 diffuse large B-cell lymphoma Mingzhi Zhang Unknown No outcome recorded
Phase 4 NCT02752815 Jun 2016 → Oct 2022 diffuse large B-cell lymphoma Ruijin Hospital Unknown Met primary
Phase 4 NCT02631499 Dec 2015 → Dec 2018 hepatocellular carcinoma Fudan University Unknown No outcome recorded
Phase 4 NCT02549677 Oct 2015 → Mar 2020 breast neoplasm Ruijin Hospital Completed No outcome recorded
Phase 4 NCT02214602 Jul 2014 → Apr 2017 superficial urinary bladder carcinoma Mansoura University Completed Missed primary
Phase not applicable10 trials
— NCT07491822 Mar 2026 → Sep 2027 expected triple-negative breast carcinoma Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
— NCT05204524 Aug 2021 → Aug 2022 leiomyosarcoma Chinese Academy of Medical Sciences Unknown No outcome recorded
— NCT03647280 Dec 2018 → Sep 2020 breast cancer Zhejiang Cancer Hospital Unknown No outcome recorded
— NCT03277716 Dec 2017 → Dec 2019 hepatocellular carcinoma Fan Weijun Unknown No outcome recorded
— NCT03022123 Nov 2016 → Nov 2017 diffuse large B-cell lymphoma Hebei Medical University Fourth Hospital Unknown No outcome recorded
— NCT02358863 Feb 2015 → Nov 2016 esophageal cancer, gastric cancer Georgetown University Terminated No outcome recorded Stop: Enrollment
— NCT01159236 Sep 2010 → ? breast cancer M.D. Anderson Cancer Center Withdrawn No outcome recorded
— NCT00544505 Sep 2007 → Sep 2012 breast cancer King Faisal Specialist Hospital & Research Center Unknown No outcome recorded
— NCT00617370 Nov 2004 → Jul 2005 breast adenocarcinoma Memorial Sloan Kettering Cancer Center Completed No outcome recorded
— NCT00146588 Apr 2002 → Dec 2004 breast cancer Craig A. Bunnell, MD, MPH Completed No outcome recorded
Phase not stated1 trial · 1 met primary
— NCT00517894 — lymphoma Study Group of Medical Tumour Therapy (AGMT) No longer available Met primary
Comparator or background therapy289 trials
Phase 1 NCT07688252 Background Jul 2026 → Dec 2032 expected neuroblastoma Chang Gung Memorial Hospital Recruiting No outcome recorded
Phase 1 NCT06121570 Background Nov 2023 → Aug 2026 overdue breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
Phase 1 NCT02527746 Background Dec 2012 → Dec 2013 breast cancer, neutropenia EVIVE Biotechnology Completed No outcome recorded
Phase 1 NCT01624441 Background Aug 2012 → Sep 2013 male breast carcinoma, triple-negative breast carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT02867397 Background Jan 2012 → Aug 2015 — Disphar International B.V. Completed No outcome recorded
Show all 289 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 6

DateIssuerRelease
2025-05-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Results 从“跟随创新”到“引领突破” 安罗替尼联合化疗一线治疗软组织肉瘤mPFS延长5.5个月 cttq.com ↗
初步结果显示,试验组较对照组显著延长中位无进展生存期(mPFS)(8.57个月vs 3.02个月;HR=0.30, 95%CI 0.21-0.44, P<0.001),客观缓解率(ORR)提升近6倍(17.8% vs 2.9%),疾病控制率(DCR)显著提高(79.3% vs 54.7%)。
2025-05-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Results “国药之光”领衔12大ORAL刷屏ASCO,中国生物制药引领中国创新药企冲刺全球新 cttq.com ↗
研究结果显示,安罗替尼联合治疗组患者中位PFS延长约5.5个月,客观缓解率(ORR)、疾病控制率(DCR)显著提高,总生存期(OS)已显示出获益趋势。
2024-09-15 Merck Sharp & Dohme LLC Results KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) merck.com ↗
The five-year OS rate was 86.6% (95% CI, 84.0-88.8) for patients who received the KEYTRUDA regimen versus 81.7% (95% CI, 77.5-85.2) for patients who received the chemotherapy-placebo regimen.
2023-10-20 Merck Sharp & Dohme LLC Results Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer merck.com ↗
KEYTRUDA plus chemotherapy before surgery met one of its dual primary endpoints of pathological complete response (pCR), demonstrating a statistically significant improvement in pCR rate compared to placebo plus chemotherapy.
2019-10-22 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Regulatory VOLUNTARY ANNOUNCEMENT - ANTI-TUMOR NANODRUG "EPIRUBICIN HYDROCHLORIDE LIPOSOME INJECTION" WAS GRANTED CLINICAL TRIAL APPROVAL irasia.com ↗
ANTI-TUMOR NANODRUG “EPIRUBICIN HYDROCHLORIDE LIPOSOME INJECTION” WAS GRANTED CLINICAL TRIAL APPROVAL
2007-06-02 Eli Lilly and Company Results Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer lilly.com ↗
Results showed that adding GEMZAR to the current standard-of-care treatment was a promising regimen for patients with stage II-III breast cancer.

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 547 sources stand behind the page.

FieldValueCited text
Known as Epirubicin “In the A arm, the combined treatment with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2) and...” NCT06766266 ↗
527

“Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100...” NCT00830544 ↗

“Epirubicin (90 mg/m², intravenous infusion) combined with cyclophosphamide (600 mg/m², intravenous infusion, every 2 weeks or 3 weeks, determined by investigators) for 4...” NCT07410559 ↗

“Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600...” NCT05569811 ↗

“a) Cyclophosphamide: 750 mg/m2 i.v. drip, administered on D1; b) Doxorubicin: 50 mg/m2 i.v. drip (or Epirubicin: 70mg/m2 i.v. drip), administered on D1; c) Vincristine: 1.4...” NCT06961500 ↗

“The chemotherapy included nab-paclitaxel (100 mg/m2) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by...” PMID 39671272 ↗ Feb 2025

“Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by...” NCT06671262 ↗

“A single early intravesical instillation of standard-of-care chemotherapy (epirubicin, mitomycin, or gemcitabine) administered into the urinary bladder shortly following TURBT...” NCT07804056 ↗

“The anthracycline may be either Epirubicin (body surface area-adjusted 50 mg/m²) or Liposomal Doxorubicin (body surface area-adjusted 30 mg/m²) combined with Cyclophosphamide...” NCT06914440 ↗

“Six cycles of standard induction chemotherapy consisting of cyclophosphamide, vincristine, doxorubicin (or epirubicin), etoposide, and cisplatin administered according to the...” NCT07688252 ↗

“Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three...” NCT02586025 ↗

Show 517 more sources

Known as EADM “Epirubicin(EADM)” NCT02638857 ↗
Known as Ellence “Both epirubicin (Ellence); Pfizer Pharmaceuticals, New York, NY, http://www.pfizer.com) and thalidomide (Thalomid); Celgene Corporation, Warren, NJ, http://www.celgene.com)...” PMID 15967833 ↗ Jun 2005
1

“Epirubicin (trade name Ellence)” NCT01204801 ↗

Known as EPI “A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX) T: paclitaxel (PTX)” NCT03876886 ↗
2

“Combination of Docetaxel (DTX) and Epirubicin (EPI)” NCT02392845 ↗

“Epirubicin (EPI) belongs to anthracyclines” NCT03151044 ↗

Known as epidoxorubicin “Treatment in this multicentric neoadjuvant pilot study consisted of panitumumab (9 mg/kg) for eight cycles q.3 weeks combined with four cycles of 5-fluorouracil, epidoxorubicin...” PMID 24827135 ↗ May 2014
4

“Drug: Epidoxorubicin(15 mg/m2, iv, on days 1-4)” NCT01868828 ↗

NCT00429299 ↗

NCT03192644 ↗

NCT00559845 ↗

Known as Epirubicin hydrochloride “To determine the pathologic response rate (\>= 95% necrosis) after preoperative treatment with sorafenib (sorafenib tosylate), epirubicin (epirubicin hydrochloride),...” NCT02050919 ↗
33

“Drugs used in chemotherapy, such as mitomycin C and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by...” NCT01094964 ↗

“Patients with a poor response to docetaxal/herceptin will receive Fluorouracil, Epirubicin Hydrochloride, Cyclophonsphamide (FEC) injection by drip every 3 weeks.” NCT03879577 ↗

“Patients then receive standard chemotherapy comprising epirubicin hydrochloride IV, cyclophosphamide IV, and fluorouracil IV on day 1.” NCT00872625 ↗

“All patients receive epirubicin hydrochloride IV over 30-60 minutes and cyclophosphamide IV over 60 minutes on day 1.” NCT00288002 ↗

“Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide” NCT04418154 ↗

“Patients receive epirubicin hydrochloride IV over 2 hours and carboplatin IV over 30 minutes on day 1” NCT00486356 ↗

“Patients receive epirubicin hydrochloride and cyclophosphamide in weeks 1-3.” NCT00379015 ↗

“Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip” NCT06009627 ↗

“epirubicin hydrochloride IV over 10 minutes” NCT00820547 ↗

“Epirubicin hydrochloride for injection.” NCT07424287 ↗

Show 23 more sources

Known as Epirubicin, Pfizer “Epirubicin, Pfizer” NCT01479036 ↗
Known as Epirubicin: Epirubicin Teva “Epirubicin: Epirubicin Teva” NCT01301040 ↗
Known as Epirubicine “Epirubicine, Cyclophosphamide, Paclitaxel” NCT03515798 ↗
5

“Epirubicine 100 mg/m² i.v.” NCT00847444 ↗

NCT00196872 ↗

NCT01351038 ↗

NCT00773695 ↗

NCT00162695 ↗

Known as Farmorubicin “Patients with advanced breast cancer are randomized to first-line chemotherapy with a combination of epirubicin (Farmorubicin®) and paclitaxel (Taxol®) alone (ET) or in...” NCT01433614 ↗
1

“Epirubicin (Farmorubicin) at the dose of 90mg/m\^2 IV every 3 weeks for 6 consecutive cycles” NCT00431795 ↗

Known as Pharmorubicin “A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX) T: paclitaxel (PTX)” NCT03876886 ↗
2

“epirubicin(Pharmorubicin) 50mg/m2” NCT01964027 ↗

“Epirubicin (Pharmorubicin®)” NCT00130936 ↗

Action Inhibit “epirubicin also has inhibitory effect on topoisomerase II” NCT03151044 ↗
Modality Small molecule “anthracycline-based adjuvant therapy” NCT00162812 ↗
Route Intravenous “epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.” NCT00002529 ↗